2. QUALITATIVE AND QUANTITATIVE COMPOSITION
Use in leukaemia and myelodysplasia Limited clinical data suggest that the effect on time to recovery of severe neutropenia between pegfilgrastim and filgrastim is ...
Download 2. QUALITATIVE AND QUANTITATIVE COMPOSITION
Information
Domain:
Source:
Link to this page:
Documents from same domain
ADVANTAN Presentation Uses - Medsafe
www.medsafe.govt.nzADVANTAN® Data Sheet Page 1 of 9 ADVANTAN® Methylprednisolone aceponate 0.1% ointment/cream . Presentation 1 g cream or ointment contains 1 mg (0.1%) methylprednisolone aceponate.
LOXALATE 1. Product Name - Medsafe Home Page
www.medsafe.govt.nzPage 5of 21 at risk, such as the elderly, or patients with cirrhosis, or if used in combination with other medications which may cause hyponatraemia.
DATA SHEET 1 CLEXANE AND CLEXANE FORTE ... - …
www.medsafe.govt.nzNew Zealand Data Sheet June 2017 . clexane-clexane-forte-ccdsv13-dsv18-16jun17 Page 2 . 100 mg injection enoxaparin sodium 100mg (equivalent to …
SEPTANEST Articaine hydrochloride 4% with …
www.medsafe.govt.nzSEPTANEST Articaine hydrochloride 4% with adrenaline 1:100,000 Injection for local and regional dental anaesthesia DESCRIPTION SEPTANEST is a sterile aqueous solution that contains articaine hydrochloride 4% (40 mg/mL) with adrenaline acid tartrate in a 1:100,000 strength.
BOOSTRIX - Medsafe Home Page
www.medsafe.govt.nz1 BOOSTRIX®. Combined diphtheria, tetanus, acellular pertussis (dTpa) vaccine . CONSUMER MEDICINE INFORMATION WHAT IS IN THIS LEAFLET? This leaflet answers some of the common questions about BOOSTRIX vaccine.
NEW ZEALAND DATA SHEET - Medsafe
www.medsafe.govt.nzNEW ZEALAND DATA SHEET Cymevene ® DS 170831 2 of 26 Caution: Cymevene must only be administered by IV infusion over 1 hour, preferably via a
Edition Draft - Medsafe
www.medsafe.govt.nzPart 4, Ed Draft Page 2 of 9 Section 1: Good Manufacturing Practice Documentation 1.1. When is GMP Documentation Required? Medsafe requires evidence of Good Manufacturing Practice (GMP) compliance for
Data Sheet 1 PRODUCT NAME 2 QUALITATIVE AND …
www.medsafe.govt.nzNew Zealand Data Sheet 31 July 2017 Lantus – insulin glargine lantus-ccdsv19-dsv11-31jul17 Page 1 Data Sheet 1 PRODUCT NAME Lantus 100 IU/mL solution for injection in 10 …
NEW ZEALAND DATA SHEET MESTINON® - Medsafe
www.medsafe.govt.nzNEW ZEALAND DATA SHEET MESTINON® MESTINON Page 4 of 8 As the severity of myasthenia gravis often fluctuates considerably, particular care is required to
DATA SHEET PREDNISONE - Medsafe
www.medsafe.govt.nz• Epilepsy and/or seizure disorder • Peptic ulceration • Previous steroid myopathy • Tuberculosis • Patients with myasthenia gravis receiving anticholinesterase therapy since
Related documents
Buku Haemopoietic 6.0:Layout 1 8/14/09 5:24 PM …
moh.gov.myForeword Director General of Health Malaysia 6 Articles 1.0 Introduction 11 2.0 General 12 3.0 Transplant Unit 13 3.1 Clinical 13 3.2 Laboratory 14 3.3 Supportive Services 15
A Textbook of Clinical Pharmacology and …
pharmaresearchlibrary.comA Textbook of Clinical Pharmacology and Therapeutics FIFTH EDITION JAMES M RITTER MA DPHIL FRCP FMedSci FBPHARMACOLS Professor of Clinical Pharmacology at King’s College London School of Medicine,
Paediatric Oncology Shared Care Service Level …
www.londoncancer.org1 Paediatric Oncology Shared Care Service Level Agreement - for inclusion within POSCU operational Policy Measure 14-7A-102 The North and South Thames Children’s Cancer Network Coordinating Groups
LCA Haemato-Oncology Clinical Guidelines
www.londoncanceralliance.nhs.ukLCA Haemato-Oncology Clinical Guidelines Acute Leukaemia s and Myeloid Neoplasms. Part 1: Acute Lymphoblastic Leukaemia . April 2015
LCA Haemato-Oncology Clinical Guidelines
www.londoncanceralliance.nhs.ukLCA Haemato-Oncology Clinical Guidelines Acute Leukaemias and Myeloid Neoplasms . Part 2: Acute Myeloid Leukaemia . April 2015
2013 - St. James's Hospital
www.stjames.ie3 Clinical Service Directorates LabMed Directorate Haematology, Biochemistry, Immunology, Transfusion Medicine, Histopathology, Cytopathology,
Second Meeting of the Subcommittee of the …
www.who.intSecond Meeting of the Subcommittee of the Expert Committee on the Selection and Use of Essential Medicines Geneva, 29 September to 3 October 2008
POSITION COSASTATEMENT POSITION ON …
www.cosa.org.auSUPPORTING ORGANISATIONS Australasian Gastro-Intestinal Trials Group Australasian Leukaemia & Lymphoma Group Australasian Lung Cancer Trials Group